Axicabtagene ciloleucel (axi-cel), a form of CAR-T therapy appears to be safe and has encouraging signs of efficacy in treating both lymphoma of the brain and spinal cord injury.
Disabling the CD161 pathway restores the T-cell's ability to attack gliomas and extends lifespan in animal models of brain cancer.
Glioma patients whose tumors were hypermutated showed no significant benefit when treated with checkpoint blockers.
